Zobrazeno 1 - 6
of 6
pro vyhledávání: '"J Allyson, Hays"'
Autor:
Rafał Machowicz, Paul La Rosée, Paivi Miettunen, Gunnar Lachmann, Kai Lehmberg, Gernot Beutel, Karin Beutel, Matt S. Zinter, Jan-Inge Henter, Jan A M van Laar, Melissa Hines, Michael B. Jordan, Bita Shakoory, Gritta Janka, J Allyson Hays, AnnaCarin Horne, Tatiana von Bahr Greenwood
Publikováno v:
Critical Care Medicine, 50(5), 860-872
OBJECTIVE: Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome that often requires critical care support and remains difficult to diagnose. These guidelines are meant to aid in the early recognition, diagnosis, supportive care, and tre
Autor:
Lei Zhang, Elena Repnikova, Laura E Brown, David L Zwick, Keith J. August, Robert E. Garola, Laura C. McCarthy, J Allyson Hays, Laurel M Bowen, Linda D. Cooley, Weijie Li, Melissa Gener
Publikováno v:
Journal of Clinical Pathology. 73:563-570
AimsHistorically, there has been no consensus on the diagnostic classification of high-grade B-cell lymphoma (HGBCL) with morphological features of Burkitt lymphoma (BL) but no MYC gene rearrangement (MYC-negative). The 2016 WHO classification of tum
Publikováno v:
Neonatal Hematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a9f7638c27151ede6043389aa5dd365
https://doi.org/10.1017/9781108773584.024
https://doi.org/10.1017/9781108773584.024
Autor:
Lei, Zhang, Laura E, Brown, Laurel M, Bowen, Laura C, McCarthy, Linda D, Cooley, Elena, Repnikova, Melissa A, Gener, Robert, Garola, Keith J, August, J Allyson, Hays, David L, Zwick, Weijie, Li
Publikováno v:
Journal of clinical pathology. 73(9)
Historically, there has been no consensus on the diagnostic classification of high-grade B-cell lymphoma (HGBCL) with morphological features of Burkitt lymphoma (BL) but noWe retrospectively reviewed cases of mature HGBCL diagnosed at our hospital be
Publikováno v:
Pediatric bloodcancerREFERENCES. 67(3)
BACKGROUND The treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children is challenging and new treatment options are needed. Bortezomib is a proteasome inhibitor with activity in pediatric acute lymphoblastic leukemia. Addin
Autor:
Sarah L Tsai, Carol J Saunders, Julie A. Cakici, Greyson P Twist, Isabelle Thiffault, Emily G. Farrow, Laurel K. Willig, Shannon L. Carpenter, Howard W. Kilbride, Ryan McDonough, Mitchell Creed, Ryan T. Fischer, Josh E Petrikin, J Allyson Hays, Jamie L Rosterman, Aaron Noll, Mark A. Clements, Laurie D. Smith, Sarah E Soden, Stephen F. Kingsmore, Suzanne Herd, Lee Zellmer, Neil A. Miller, Patria M Alba
Publikováno v:
The Lancet. Respiratory medicine. 3(5)
Summary Background Genetic disorders and congenital anomalies are the leading causes of infant mortality. Diagnosis of most genetic diseases in neonatal and paediatric intensive care units (NICU and PICU) is not sufficiently timely to guide acute cli